Aimmune Therapeutics, Inc. (AIMT): Price and Financial Metrics


Aimmune Therapeutics, Inc. (AIMT)

Today's Latest Price: $34.49 USD

0.10 (-0.29%)

Updated Oct 13 8:00pm

Add AIMT to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

AIMT Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for AIMT is 0 -- better than only 9% of US stocks.
  • AIMT's price/sales ratio is 3,925.87; that's higher than the P/S ratio of 99.73% of US stocks.
  • With a year-over-year growth in debt of 177.57%, Aimmune Therapeutics Inc's debt growth rate surpasses 91.61% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Aimmune Therapeutics Inc, a group of peers worth examining would be RVNC, ADVM, MRTX, AUPH, and VTVT.
  • Visit AIMT's SEC page to see the company's official filings. To visit the company's web site, go to www.aimmune.com.

AIMT Stock Price Chart Interactive Chart >

Price chart for AIMT

AIMT Price/Volume Stats

Current price $34.49 52-week high $37.00
Prev. close $34.59 52-week low $10.09
Day low $34.48 Volume 987,254
Day high $34.56 Avg. volume 1,714,599
50-day MA $25.92 Dividend yield N/A
200-day MA $21.96 Market Cap 2.26B

Aimmune Therapeutics, Inc. (AIMT) Company Bio


Aimmune Therapeutics is a clinical-stage biopharmaceutical company, engages in the development of desensitization treatments for peanut and other food allergies. The company was founded in 2011 and is based in Brisbane, California.


AIMT Latest News Stream


Event/Time News Detail
Loading, please wait...

AIMT Latest Social Stream


Loading social stream, please wait...

View Full AIMT Social Stream

Latest AIMT News From Around the Web

Below are the latest news stories about Aimmune Therapeutics Inc that investors may wish to consider to help them evaluate AIMT as an investment opportunity.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Aimmune Therapeutics, Inc. - AIMT

NEW YORK , Sept. 18, 2020 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City , is investigating Aimmune Therapeutics, Inc. ("Aimmune" or the "Company") ( AIMT ) relating to the sale of the Company to Sociétés des Produits Nestlé, S.A. Under the terms of the agreement, Aimmune shareholders are anticipated to receive $34.50 per share for each share of Aimmune they own. … Full story available on Benzinga.com

Benzinga | September 18, 2020

Merger Arbitrage Analysis And Spread Performance - September 13, 2020

This weekly column explains the reasons behind the movement in a selection of the largest U.S. cash merger arbitrage spreads from the past week as calculated by Merger Arbitrage Limited. We analyze the attractiveness and profitability of each spread going forward and indicate the trading position or action we have...

Mal Spink, CFA on Seeking Alpha | September 14, 2020

Development of Needle Free Alternatives for Treatment of Anaphylaxis Underway as Aquestive Therapeutics Launches Phase 1 Clinical Trial - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--ResearchAndMarkets.com published a new article on the allergy drugs industry "Allergy Drugs" Nestle has agreed to buy Aimmune Therapeutics Inc in a $2.6 billion deal. Nestle has built a large health science business focused on dietary management and the deal will add Aimmunes's Palforzia to its portfolio. Palforzia is the first FDA approved treatment to reduce the frequency and severity of allergic reactions to peanuts in children and teenagers. The drug is derived from

Business Wire | September 11, 2020

Aimmune Therapeutics: A Bargain For A Potential Blockbuster Therapy

Investment Thesis Earlier this year, Aimmune Therapeutics, Inc. (AIMT) unveiled Palforzia, the first and only FDA approved therapy to suppress the effects of peanut allergy. The lockdown measures hindered its market launch, and the company failed to realize sales to arrest the stock’s decline. Despite a rich portfolio of drugs...

Dulan Lokuwithana on Seeking Alpha | September 9, 2020

AIMMUNE INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of  Aimmune Therapeutics Inc. - AIMT

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of  Aimmune Therapeutics Inc. (NasdaqGS: AIMT) to Sociétés des Produits Nestlé, S.A. Under the terms of the proposed transaction, shareholders of Aimmune will receive only $34.50 in cash for each share of Aimmune that they own. KSF is seeking to determine whether this consideration and the process that led to i

Business Wire | September 4, 2020

Read More 'AIMT' Stories Here

AIMT Price Returns

1-mo 0.55%
3-mo 137.53%
6-mo 87.24%
1-year 22.92%
3-year 10.40%
5-year 133.51%
YTD 3.05%
2019 39.92%
2018 -36.75%
2017 84.94%
2016 10.84%
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.806 seconds.